Please login to the form below
ENSEMBLE
This page shows the latest ENSEMBLE news and features for those working in and with pharma, biotech and healthcare.
US COVID-19 booster programme expanded
The company points out that the real-world data is consistent with its phase 3 ENSEMBLE trial results. ... J&J also reported results from a second trial, the phase 3 ENSEMBLE 2 study, which looked at a second, booster shot of the vaccine given 56 days
Latest news
-
J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant
A pre-print paper, submitted to bioRxiv yesterday, includes analysis from blood samples taken from a group of participants in J&J’s phase 3 ENSEMBLE COVID-19 vaccine study.
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
The data, presented virtually at the American Academy of Neurology (AAN) annual meeting, comes from the open label phase IIIb ENSEMBLE and a post-hoc analysis of the phase III ORATORIO ... studies. In the ENSEMBLE study, 85% of recently diagnosed RRMS
-
WHO backs emergency use of J&J’s one-dose COVID-19 vaccine
In the phase 3 ENSEMBLE trial, J&J’s vaccine was 66.1% effective overall in preventing moderate-to-severe COVID-19, 28 days after vaccination.
-
J&J’s one-dose COVID-19 vaccine granted EU authorisation
J&J submitted its vaccine for a CMA in the EU in February, basing the submission on top-line efficacy and safety data from the phase 3 ENSEMBLE trial. ... The ENSEMBLE study was conducted in eight countries across three continents, with 44% of
-
Merck & Co to help produce J&J’s COVID-19 vaccine in the US
J&J’s phase 3 ENSEMBLE trial found that the vaccine was 66% effective overall in preventing moderate-to-severe COVID-19, 28 days after vaccination.
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
A cancer journey is like a complex novel, with a storyline that involves an ensemble of characters across a variety of settings, encountering barriers and plot twists every step of the
-
Stepping out
The ‘one-size-fits-all’ approach will not change behaviours.”. An ensemble performance. Naturally, patients are the focal point of behaviour change programmes.
-
Integrated thinking - it’s both art and science
While these guys may not sound as good together as the ensemble musical cast of Station to Station or “Heroes”, there's little doubt this approach represents a refreshing challenge to
-
Pharma deals during November 2012
230. Cipla Medpro / Cipla. Acquisition. Generics. 215. Ensemble Therapeutics / Boehringer Ingelheim.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
